A Multi-national, Multi-center, Double-blind, Randomized, Parallel Study Comparing the Efficacy and Safety of Valsartan/Amlodipine 160/5 mg to Valsartan 160 mg Alone in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Valsartan 160 mg Monotherapy.
Phase of Trial: Phase III
Latest Information Update: 17 Oct 2017
At a glance
- Drugs Amlodipine/valsartan (Primary) ; Valsartan
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Novartis
- 09 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jun 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
- 02 Nov 2009 New trial record